2023
DOI: 10.1186/s12957-023-03029-2
|View full text |Cite
|
Sign up to set email alerts
|

De-escalating chemotherapy for stage I–II gastric neuroendocrine carcinoma? A real-world competing risk analysis

Abstract: Background The role of adjuvant chemotherapy in gastric neuroendocrine neoplasms (GNEC) has not been well clarified yet. The study was designed to investigate the potential effect of adjuvant chemotherapy in stage I–II GNEC patients and construct a predictive nomogram. Method Stage I–II GNEC patients were included in the Surveillance, Epidemiology, and End Results (SEER) database and divided into chemotherapy and no-chemotherapy groups. We used Kap… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 21 publications
0
0
0
Order By: Relevance